医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evecxia Licenses Additional IP from NUS, NUH and NTU in Singapore

2018年10月11日 PM09:00
このエントリーをはてなブックマークに追加


 

RESEARCH TRIANGLE PARK, N.C.

Evecxia, Inc., a privately funded, clinical stage biopharmaceutical company, today announced that it has licensed exclusive, world-wide rights to develop and commercialize novel formulations for improving the bioavailability and pharmacokinetics of 5-hydroxytryptophan (5-HTP) from:

  • National University of Singapore (NUS), acting through its Duke-NUS Medical School (Duke-NUS)
  • National University Hospital (NUH)
  • Nanyang Technological University, Singapore (NTU), through its innovation and enterprise company NTUitive Pte. Ltd

The joint intellectual property licensed from NUS-NUH-NTU was developed using funding from the National Health Innovation Centre Singapore (NHIC) under its Innovation to Develop (I2D) grant scheme.

“This license agreement with DUKE-NUS, NUH and NTUitive strengthens our patent portfolio with additional protection, geographic coverage, and years of exclusivity to EVX-101, our lead product candidate,” said John Kaiser, CEO of Evecxia.

Under the terms of the agreement, Evecxia will immediately assume full development and commercialization of EVX-101 and any other product candidates emanating from the license agreement with Duke-NUS, NUH and NTU. In addition to an upfront licensing fee Duke-NUS, NUH and NTU will receive milestone and low single-digit royalty payments.

About Evecxia

Evecxia Inc. is a privately funded, clinical stage pharmaceutical company co-founded by Duke neuropsychopharmacologists, Dr. Marc Caron and Dr. Jacob Jacobsen. Evecxia is located in the Research Triangle Park, NC. Evecxia’s primary mission is to develop and commercialize EVX-101 to treat patients suffering from disabling, common, and costly neuropsychiatric conditions in which current therapies, in many cases, are sub-optimal.

Evecxia is the first company dedicated to realizing the therapeutic potential of 5-HTP via specialized prescription combinations and drug delivery dosage forms.

About EVX-101

EVX-101 is a proprietary oral slow-release formulation of 5-HTP and low-dose carbidopa. Initially, EVX-101 will be developed and positioned as a first-choice adjunctive treatment in depressed patients responding inadequately to conventional antidepressants. As an antidepressant, the development of EVX-101, a new chemical entity (NCE), is uniquely de-risked because the therapeutic mechanism—elevating extracellular serotonin beyond the effect of conventional SSRI/SNRI antidepressants—enjoys human proof-of-concept (POC) for efficacy and safety.

For more information about the Company and its product candidate, visit www.evecxia.com or contact info@evecxia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005067/en/

CONTACT

Evecxia, Inc.
John Kaiser, CEO
info@evecxia.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
  • Tilray®宣布成立国际顾问委员会
  • 武田和纽约科学院宣布2019年度科学创新者奖获奖人
  • AMRA、身体組成の非侵襲的測定を実現する磁気共鳴診断ソフトウエアアプリケーションのAMRA® Profilerで米国FDAの承認を取得
  • AMRA用于机体成分无创评估的磁共振诊断软件AMRA® Profiler获得美国FDA核准